New version of ovarian cancer drug tested in 40 patients
NCT ID NCT07371104
First seen Jan 28, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study tests if a new version of the drug olaparib (DWZ2501) works the same as the current version (DWC202510) in people with advanced ovarian cancer linked to a BRCA gene mutation. About 40 adults who are already stable on olaparib will take both versions at different times to compare drug levels and safety. The goal is to see if the new version can be used instead of the current one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutional Review Board of Seoul National University Hospital
RECRUITINGSeoul, Jongno-gu, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.